Ozempic and Wegovy have received a lot of publicity as revolutionizing treatment options for obesity. Both medications form a class of GLP-1 receptor agonists, which mimic a hormone in the body called glucagon-like peptide-1 and are involved in the regulation of appetite and blood sugar. Indeed, in initial clinical studies, the majority of those on the drugs lost 15% to 22% of body weight, hence much optimism. For most patients, these medications are underwhelming for about 20% of patients due to minimal weight loss or other challenges.

Take a closer look at why the weight loss drugs may not work for everyone, together with what options exist when they don't deliver the expected outcomes.

Why Weight Loss Drugs May Not Work

While GLP-1 receptor agonists have produced phenomenal responses in a majority of patients, it remains a reality that these drugs work differently for different people. Here's why:

1. Genetic and Hormonal Variability

Weight loss medications interact with complex systems in the body that differ from person to person. Genetics, hormones, and individual brain responses to energy regulation play significant roles in determining how a person responds to drugs like Ozempic and Wegovy.

2. Underlying Medical Conditions

Other conditions, such as sleep apnea, may be prevalent and prevent or delay the achievement of weight loss goals. Prescription drugs like antidepressants, steroids, or contraceptives are other medications that can nullify weight loss medication benefits.

3. Unrealistic Expectations

Often, they come to these medications with enormous hopes; expecting the promised rapid and dramatic weight loss. Progress creates disappointment if it has not stalled. In patients who rigidly follow recommended lifestyle modifications, frustration and disappointment are most common.

Why it is Important to Identify Non-responders

For most patients, the effectiveness of GLP-1 receptor agonists is evident within a few weeks of treatment. Weight loss typically begins within a few weeks of initiating therapy and tends to increase with dosage. However, some patients respond very little, if at all, despite strict adherence to their regimen.

For nonresponders, this can feel like a dead end. However, understanding the unique complexities of obesity is essential. This condition stems from brain dysfunction, and the pathways that contribute to weight regulation differ among individuals.

Alternative Treatment Options

When Ozempic or Wegovy doesn’t yield desired results, there are still many paths to explore:

1. Switching to Another GLP-1 Drug

For example, some patients who don't respond well to one GLP-1 receptor agonist might find success with another drug in the same class. Newer medications, such as Zepbound, target other hormone pathways and seem promising even for those not responsive to earlier drugs.

2. Use of Older Medications

While there is much to say about newer drugs, older treatments can still be useful and work for some patients. One can also seek the help of a medical provider specializing in obesity treatments in order to identify the best alternatives.

3. Lifestyle Changes

Diet, exercise, sleep, and stress management continue to be integral components of any weight loss program. New changes may be small but can make an enormous difference in one's health and success.

4. Medical Management of Obesity

It is a complex disorder, and most patients should receive a multidisciplinary treatment. Collaboration with an obesity-aware doctor may mean access to tailored treatment plans, ranging from psychological support all the way to metabolic testing, and many others.

Why Side Effects of Weight Loss Drug Ozempic May Be a Barrier

For others, side effects like nausea, vomiting, or diarrhea hinder them from continuing with these drugs. These symptoms often reduce as the body becomes accustomed, but for some, they might be severe enough to stop treatment altogether. In those instances, alternative drugs or procedures become vital to find.

Long-term effects of Ozempic or Wegovy on the Brain

Another largely unexplored area relates to GLP-1 drugs' long-term effects on the brain's regulation of hunger and satiety. Although GLP-1 drugs suppress appetite and can lead to effective weight loss, emerging research suggests that they may also affect brain reward mechanisms, changing the way patients experience foods.

This aspect could prove of paramount significance in the future treatment of obesity. Perhaps GLP-1 receptor agonists do indeed affect and rewire the brain's reward pathways and will thus provide sustained benefits beyond discontinuation. However, more research is required to understand this phenomenon fully.

While for many, Ozempic and Wegovy have revolutionized obesity treatment, these are certainly not a one size fits all. Nonresponders need not lose hope- alternative strategies and medications abound. A consultation with an obesity expert healthcare provider is essential to put together a comprehensive, tailored treatment plan.

The route toward effective weight loss may be challenging, but with the evolution of obesity medicine and a better understanding of individual needs, there is a path forward for everyone.

For most parents, the toddler years are filled with first words, wobbly steps and dreams of the future. For Gus and Emily Forrester, those moments are now overshadowed by a diagnosis they describe as “every parent’s worst nightmare.”

Their two-year-old daughter, Leni, has been diagnosed with Sanfilippo Syndrome Type B, a rare genetic condition often referred to as childhood dementia. The disorder, formally known as Mucopolysaccharidosis type III, gradually robs children of their physical and cognitive abilities.

In an interview with ITV News, Leni’s parents spoke about the devastating reality of the condition, which has no approved cure or widely available treatment.

“All your dreams for your child's future are taken away,” her mother, Emily, said. “To be told that she has this condition, and there is no treatment and no cure and no support… it’s completely earth-shattering.”

What Is Childhood Dementia?

Sanfilippo Syndrome is a neurodegenerative disorder caused by the body’s inability to break down certain complex sugars. Over time, these substances build up in the brain, leading to progressive damage.

According to Cure Sanfilippo Foundation, symptoms usually begin appearing between the ages of one and six. Children may initially show mild developmental delays, but the disease gradually worsens, affecting speech, mobility and behaviour.

As the condition advances, many children lose the ability to talk, walk and recognise loved ones. Life expectancy is often limited to the early teenage years.

Emily explained the process in stark terms. Without treatment, she said, Leni’s body will slowly be overwhelmed by “toxic waste,” causing irreversible damage.

The Urgency of Early Treatment

For families like the Forresters, time is not just precious, it is critical.

“Early treatment is key for these children,” Emily said. “If she has to wait six months, that could mean she can no longer talk. If she waits 12 months, that could mean she loses the ability to walk.”

Although experimental therapies, including gene-based approaches, are being developed, access remains a major hurdle. Some clinical trials are expected to take place in the United States later this year, but Leni is not currently eligible.

Her parents are now campaigning for UK patients to be included in these trials, arguing that promising science already exists but remains out of reach for many families.

A Family's Fight For Hope

In response to the diagnosis, the Forresters have launched a fundraiser to support Leni’s care and potential treatment options. They have also pledged to donate part of the funds to Great Ormond Street Hospital, where Leni is receiving care, and to the Cure Sanfilippo Foundation, which supports affected families.

So far, donations have crossed $250,000, reflecting the growing awareness and concern around rare childhood conditions.

Leni’s father, Gus, said the emotional toll of the diagnosis is hard to put into words. “As parents, your role is to protect your children and provide every opportunity you can. Without any treatment, her future and her reality is very, very dark.”

Beyond fundraising, the couple is also raising awareness about childhood dementia and advocating for newborn screening programmes that could help detect such conditions earlier.

Experts working on experimental therapies say greater government investment is urgently needed. Without it, many children may never benefit from treatments that could slow or alter the course of the disease.

For now, Leni remains a cheerful two-year-old, full of life and affection. But for her parents, every passing day is a reminder of how quickly that could change, and how urgently answers are needed.

Every year, March 24 is observed as World Tuberculosis Day to spread awareness about the infectious disease. In India, it remains one of the most pressing infectious diseases. Dr Arup Halder, Consultant Pomologist at CK Birla Hospitals, CMRI says that India still accounts for roughly a quarter to over a quarter of world's tuberculosis or TB cases. "In 2023–2024, India reported around 25–26 lakh TB patients out of an estimated 27 lakh cases, reflecting improved detection but also highlighting a persistently high burden," he points out.

Also Read: Harish Rana Taken Off Food And Water Support For Over 10 Days; Waiting For Passive Euthanasia

While TB incidence has fallen by about 20 per cent since 2015 and mortality has also declined to roughly 21 deaths per lakh population, it still remains well above national elimination targets for 2025.

TB Could Happen Even Without A Persistent Cough

What makes TB so difficult to eliminate? While many associate TB with persistent coughing, studies show that 80 per cent of patients do not show the symptoms of cough that is "presumed" to be a common symptom. This is why, TB could go ignored until it is too late.

A research led by Amsterdam UMC and the Amsterdam Institute for Global Health and Development analyzed data on more than 600,000 individuals in Africa and Asia and found that around 82.8 per cent of those with TB had no persistent cough. The study also found that 62.5 per cent had no cough at all. The findings were published in the Lancet Infectious Diseases.

Also Read: Perez Hilton Spent 21 Days In Hospital After Taking Medication on an Empty Stomach

The study in fact noted that this could be the "probable reason why, despite huge efforts to diagnose and treat the disease, the tb burden across Africa and Asia is hardly declining". Frank Cobelens, Professor of Global Health at Amsterdam UMC and Senior Fellow at the AIGHD says, "A persistent cough is often the entry point for a diagnosis, but if 80 per cent of those with TB do not have one, then it means that a diagnosis will happen later, possibly after the infection has already been transmitted to many others, or not at all."

Another 2019 study published in Elsevier notes: "Coughing does not appear to be a necessary prerequisite for TB transmission." The study further mentions, "Frequency of cough is associated with infectivity but this does not imply mechanistic causality for TB transmission."

Does It Mean Coughing Is Harmless?

The simple answer to this is: No. Coughing does not mean harmless, especially when it is a persistent one. The study only shows that TB does not always mean persistent coughing, however, if one experiences this symptom, they should always get a test done and should not ignore the symptoms.

Researchers from The University of Texas at Dallas' Center for Advanced Pain Studies working with colleagues from UT Southwestern Medical Center note that TB coughing could cause pain. This is one of the way one can distinguish the symptoms. The findings published in journal Cell notes that before this study, "no one had even shown that TB produces an irritant that acts directly on the sensory innervation of the lungs".

Corresponding author Dr Michael Shiloh, associate professor of internal medicine and microbiology at UT Southwestern said, "People with active tuberculosis can cough for months and spread disease even when they are receiving appropriate treatment."

Read: World Tuberculosis Day 2026: Theme, Origin, And Significance

What Is India Doing To Control TB Cases?

On World TB Day, President Droupadi Murmu stressed that TB continues to pose a significant public health challenge and has affected millions of lives across the world. She urged all stakeholders to work together with collective resolve to end TB once for all.

To act on it, Union Health Minister Jagat Prakash Nadda will launch a series of initiatives, including 'TB Mukt Bharat Abhiyaan - 100 Days Campaign', the TB Mukt Bharat App, and the TB Mukt Urban Ward Initiative. These measures are designed to strengthen the case detection, improve treatment adherence, and enhance last-mile delivery of TB services, especially in high-burden areas. The initiatives have also been aligned with the objectives of the National Tuberculosis Elimination Programme.

From physical problems like fatigue and vision problems, people who survive the deadly bacterial meningitis are likely to live with long-term fatigue and vision problems, as well as be at high risk of suicide, according to a new study.

The study comes as the UK is experiencing an outbreak of meningitis in Kent, that began among students who visited Club Chemistry in Canterbury between March 5 and 7.

Although bacterial meningitis is treatable, it requires prompt, often immediate treatment for better recovery. Yet patients are likely to face the risk of fatal or long-term complications -- from physical, psychological, and social impacts, said researchers from the University of Otago, The Conversation reported.

The new findings, based on 16 cases from New Zealand, who reportedly suffered the fatal disease, showed that multiple chronic after-effects is permanent in some, while in others, it dragged on for years. The effects include:

• fatigue,
• difficulties with concentration,
• memory and emotional regulation,
• persistent headaches,
• issues with mobility, vision, and hearing.

• anxiety,
• depression
• suicidality.

"Our findings demonstrate that bacterial meningitis is much more than a life-threatening infection. It is an acute disease with serious, chronic after-effects which are poorly understood and often go unrecognised," the researchers said.

Kent Meningitis Outbreak

The bug that causes the infection has been identified as the known strain of meningitis B, and MenB vaccines will be offered to 5,000 students living in the University of Kent halls of residence in Canterbury.

Meanwhile, the UKHSA chief executive, Susan Hopkins, said the outbreak "looks like a super-spreader" event with "ongoing spread" through universities' halls of residence.

"There will have been some parties, particularly around this, so there will have been lots of social mixing. I can't yet say where the initial infection came from, how it's got into this cohort, and why it's created such an explosive amount of infections," she added.

As per Trish Mannes, UKHSA Regional Deputy Director for the South East, even after two doses, the MenB vaccine “does not protect against all strains of meningococcal disease, nor against all infections that can cause meningitis. It also does not prevent the bacteria from being carried and spread in the community”.

The UKHSA thus warned people to be aware of the signs and symptoms of invasive meningococcal disease, and to seek immediate medical attention if they or anyone they know develops these signs and symptoms.

Common symptoms include:

• rash
• sudden onset of high fever
• severe and worsening headache
• vomiting and diarrhea
• joint and muscle pain
• seizures.